Left ventricular outflow tract (LVOT) gradients, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and New York Heart Association (NYHA) functional class were all improved after patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) were treated with mavacamten, and the medication was well-tolerated, a new analysis of the MAVA-LTE trial shows.